Literature DB >> 24871443

Current hepatitis B treatment guidelines and future research directions.

Jonathan Skupsky1, Ke-Qin Hu.   

Abstract

Hepatitis B virus (HBV) infection causes a tremendous clinical burden across the world with more than half a million people dying annually from HBV related disease. Significant advances have been made in HBV treatment in the past decade and several guidelines have been published by professional societies and expert panels. Although these recommendations have been valuable to help optimize HBV treatment, there is discordance in treatment criteria and many patients infected with HBV may fall outside of these recommendations. This paper systematically reviews the natural history of the disease and compares and contrasts the recommendations for initiation of treatment from the various societies. There is also discussion of special groups that require particular consideration and some of the open research questions and future research directions within the field.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24871443     DOI: 10.1007/s11684-014-0335-1

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  108 in total

1.  Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update.

Authors:  Myron John Tong; Leeyen Hsu; Patrick W Chang; Lawrence Mitchell Blatt
Journal:  J Gastroenterol Hepatol       Date:  2011-05       Impact factor: 4.029

Review 2.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

3.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

4.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir.

Authors:  Young Kul Jung; Ji Hoon Kim; Young Sun Lee; Hyun Jung Lee; Eileen Yoon; Eun Suk Jung; Seung Kwon Hong; Moon Kyung Joo; Jong Eun Yeon; Jong Jae Park; Jae Seon Kim; Young-Tae Bak; Kwan Soo Byun
Journal:  J Clin Gastroenterol       Date:  2010-10       Impact factor: 3.062

Review 6.  Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.

Authors:  Yun-Fan Liaw
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

7.  Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis.

Authors:  S Sato; K Suzuki; Y Akahane; K Akamatsu; K Akiyama; K Yunomura; F Tsuda; T Tanaka; H Okamoto; Y Miyakawa; M Mayumi
Journal:  Ann Intern Med       Date:  1995-02-15       Impact factor: 25.391

Review 8.  Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.

Authors:  Young Ho Lee; Sang-Cheol Bae; Gwan Gyu Song
Journal:  Int J Rheum Dis       Date:  2013-10       Impact factor: 2.454

Review 9.  Reactivation of hepatitis B virus in patients receiving chemotherapy.

Authors:  Masafumi Ikeda
Journal:  Jpn J Clin Oncol       Date:  2012-11-25       Impact factor: 3.019

10.  Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.

Authors:  Eugene R Schiff; Ching-Lung Lai; Stefanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans L Tillmann; Didier Samuel; Stefan Zeuzem; Leslie Lilly; Maria Rendina; Jean-Pierre Villeneuve; Nicole Lama; Craig James; Michael S Wulfsohn; Hamid Namini; Christopher Westland; Shelly Xiong; Gavin S Choy; Sally Van Doren; John Fry; Carol L Brosgart
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

View more
  2 in total

Review 1.  The regulatory role of activating transcription factor 2 in inflammation.

Authors:  Tao Yu; Yong Jun Li; Ai Hong Bian; Hui Bin Zuo; Ti Wen Zhu; Sheng Xiang Ji; Fanming Kong; De Qing Yin; Chuan Bao Wang; Zi Fu Wang; Hong Qun Wang; Yanyan Yang; Byong Chul Yoo; Jae Youl Cho
Journal:  Mediators Inflamm       Date:  2014-06-23       Impact factor: 4.711

Review 2.  Future Therapy for Hepatitis B Virus: Role of Immunomodulators.

Authors:  Edward A Pham; Ryan B Perumpail; Benjamin J Fram; Jeffrey S Glenn; Aijaz Ahmed; Robert G Gish
Journal:  Curr Hepatol Rep       Date:  2016-11-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.